Royal Prince Alfred Hospital (RPAH) and Melanoma Institute Australia (MIA) are seeking applications for a one year Fellowship commencing February 2024. The position is based at the RPAH but also involves work at MIA’s The Poche Centre and The University of Sydney.
This Fellowship is suitable for qualified pathologists/final year anatomical pathology trainees. The position will provide a unique opportunity for the right individual to:
• enhance their clinical diagnostic skills in pigmented lesion pathology and dermatopathology,
• obtain additional experience/training in surgical/molecular pathology and research,
• gain experience in interpretation of difficult consultation cases (>2500 annually)
• participate in the MIA translational melanoma research program
• enhance their knowledge of the treatment and care of melanoma patients.
MIA is a world leader in melanoma research, clinical care and education. It is an independent, non- profit organisation that is formally affiliated with the University of Sydney and the RPAH. The Institute is staffed by an internationally recognised multidisciplinary team of senior clinicians and researchers. The award winning MIA translational research program is supported by research funding from the National Health and Medical Research Council of Australia and Cancer Institute New South Wales. The MIA Biospecimen Bank contains the largest number of annotated melanoma specimens worldwide. The Institute is a leading site for melanoma clinical trials.
Pathology is a critical aspect of the multidisciplinary care of melanoma patients at MIA. All patients who are referred for care at MIA routinely have their pathology reviewed by MIA pathologists (over 2,000 new melanoma cases each year). The tissue pathology service for MIA is provided by the Department of Tissue Pathology and Diagnostic Oncology at the RPAH, Sydney where there is a dedicated team of pathologists with special expertise in the diagnosis of pigmented lesions (including Professor Richard Scolyer, Dr Robert Rawson, Dr Peter Ferguson and Dr Andrew Colebatch). In addition, Prof Scolyer receives a large number of consultation cases from other pathologists both nationally and internationally. These unique resources offer unparalleled opportunities to both gain clinical experience in dermatopathology and to perform translation clinical and translational research.
This position is based in the Department of Tissue Pathology and Diagnostic Oncology at the RPAH and enables the successful applicant to work within a dynamic and high volume department. The department is an academic Pathology Department in a large tertiary referral hospital and is responsible for providing a high quality diagnostic service in all areas of Anatomical Pathology including surgical pathology, molecular pathology, electron microscopy and cytopathology. It services all subspecialities and receives a large number of consultation cases.
The fellow will be expected to participate in the academic activities of the Institute. It is envisaged that the Fellows position would involve 50% clinical pathology and 50% research. They would be invited to participate in the routine reporting of the department to gain further clinical experience, if desired, at a level commensurate with their experience/qualifications.
The role would encompass the following core areas:
• Obtain training and education in the pathological diagnosis and reporting of melanocytic pathology, dermatopathology and other pathology
• Develop an understanding of pathology reporting standards
• Participate in the MIA research program on molecular determinants of risk, progression and treatment response in melanoma and other pathology research projects including the melanoma genome project.
• Participate in the MIA and RPAH training and education activities
• Present at the weekly melanoma multidisciplinary team meeting
• Gain further expertise in other areas of diagnostic and molecular pathology at a major tertiary referral centre
We are currently accepting expressions of interest and applicants should be a Fellow of the Royal College of Pathologists of Australasia (RCPA), or equivalent, or be in their final year of training by January of 2024. You must also be eligible for registration with the Medical Board of Australia.